+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Pemphigus Vulgaris - Pipeline Review, H2 2019

  • ID: 4901352
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 95 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Argenx SE
  • Cabaletta Bio Inc
  • iBio Inc
  • Novartis AG
  • Pharmapraxis
  • Rubius Therapeutics Inc
  • MORE
Pemphigus Vulgaris - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Pemphigus Vulgaris - Pipeline Review, H2 2019, provides an overview of the Pemphigus Vulgaris (Immunology) pipeline landscape.

Pemphigus vulgaris is a rare autoimmune disease that causes painful blistering on the skin and the mucous membranes. Risk factors include race, gender and age. Symptoms of pemphigus vulgaris include painful blisters that start in the mouth, skin blisters that come and go; the blisters always occur near the surface of the skin and oozing, crusting, or peeling at the blister site.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Pemphigus Vulgaris - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Pemphigus Vulgaris (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pemphigus Vulgaris (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Pemphigus Vulgaris and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 4, 1, 1, 6, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Pemphigus Vulgaris (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pemphigus Vulgaris (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Pemphigus Vulgaris (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pemphigus Vulgaris (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pemphigus Vulgaris (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pemphigus Vulgaris (Immunology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pemphigus Vulgaris (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pemphigus Vulgaris (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Argenx SE
  • Cabaletta Bio Inc
  • iBio Inc
  • Novartis AG
  • Pharmapraxis
  • Rubius Therapeutics Inc
  • MORE
Introduction
Report Coverage
Pemphigus Vulgaris - Overview
Pemphigus Vulgaris - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Pemphigus Vulgaris - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Pemphigus Vulgaris - Companies Involved in Therapeutics Development
Alexion Pharmaceuticals Inc
Argenx SE
Biogen Inc
Cabaletta Bio Inc
Daewoong Pharmaceutical Co Ltd
Declion Pharmaceuticals Inc
HanAll Biopharma Co Ltd
iBio Inc
Immunomedics Inc
Novartis AG
Octagon Therapeutics Inc
Pharmapraxis
Principia Biopharma Inc
Rubius Therapeutics Inc
Topas Therapeutics GmbH
Pemphigus Vulgaris - Drug Profiles
Pemphigus Vulgaris - Dormant Projects
Pemphigus Vulgaris - Discontinued Products
Pemphigus Vulgaris - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Pemphigus Vulgaris, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pemphigus Vulgaris - Pipeline by Alexion Pharmaceuticals Inc, H2 2019
Pemphigus Vulgaris - Pipeline by Argenx SE, H2 2019
Pemphigus Vulgaris - Pipeline by Biogen Inc, H2 2019
Pemphigus Vulgaris - Pipeline by Cabaletta Bio Inc, H2 2019
Pemphigus Vulgaris - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2019
Pemphigus Vulgaris - Pipeline by Declion Pharmaceuticals Inc, H2 2019
Pemphigus Vulgaris - Pipeline by HanAll Biopharma Co Ltd, H2 2019
Pemphigus Vulgaris - Pipeline by iBio Inc, H2 2019
Pemphigus Vulgaris - Pipeline by Immunomedics Inc, H2 2019
Pemphigus Vulgaris - Pipeline by Novartis AG, H2 2019
Pemphigus Vulgaris - Pipeline by Octagon Therapeutics Inc, H2 2019
Pemphigus Vulgaris - Pipeline by Pharmapraxis, H2 2019
Pemphigus Vulgaris - Pipeline by Principia Biopharma Inc, H2 2019
Pemphigus Vulgaris - Pipeline by Rubius Therapeutics Inc, H2 2019
Pemphigus Vulgaris - Pipeline by Topas Therapeutics GmbH, H2 2019
Pemphigus Vulgaris - Dormant Projects, H2 2019
Pemphigus Vulgaris - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Pemphigus Vulgaris, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Alexion Pharmaceuticals Inc
  • Argenx SE
  • Biogen Inc
  • Cabaletta Bio Inc
  • Daewoong Pharmaceutical Co Ltd
  • Declion Pharmaceuticals Inc
  • HanAll Biopharma Co Ltd
  • iBio Inc
  • Immunomedics Inc
  • Novartis AG
  • Octagon Therapeutics Inc
  • Pharmapraxis
  • Principia Biopharma Inc
  • Rubius Therapeutics Inc
  • Topas Therapeutics GmbH
Note: Product cover images may vary from those shown
Adroll
adroll